{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"BGB-11417"},{"type":"CodeName","name":"BGB 11417"},{"type":"Synonym","name":"B-cell lymphoma-2 inhibitor BGB-11417"},{"type":"LexicalVariant","name":"Bcl-2 inhibitor BGB-11417"},{"type":"CodeName","name":"BGB11417"},{"type":"CASRegistryName","name":"2383086-06-2"}],"definition":{"html":"An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, sonrotoclax specifically binds to and inhibits the activity of the pro-survival protein Bcl-2. This restores apoptotic processes and inhibits cell proliferation in Bcl-2-overexpressing tumor cells. Bcl-2, a protein that belongs to the Bcl-2 family, is overexpressed in various tumor cell types and plays an important role in the negative regulation of apoptosis. Its tumor expression is associated with increased drug resistance and cancer cell survival.","text":"An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, sonrotoclax specifically binds to and inhibits the activity of the pro-survival protein Bcl-2. This restores apoptotic processes and inhibits cell proliferation in Bcl-2-overexpressing tumor cells. Bcl-2, a protein that belongs to the Bcl-2 family, is overexpressed in various tumor cell types and plays an important role in the negative regulation of apoptosis. Its tumor expression is associated with increased drug resistance and cancer cell survival."},"drugInfoSummaryLink":null,"nciConceptId":"C175489","nciConceptName":"Sonrotoclax","termId":803186,"name":"sonrotoclax","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sonrotoclax"}],"links":null}